Simcere and Idorsia enter into a licensing agreement for daridorexant in China
NANJING, China, Nov. 16, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd (2096.HK, "Simcere"), an innovation and R&D-driven pharmaceutical company,and Idorsia Ltd (SIX: IDIA, "Idorsia"), specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options, announced today that they have entered into an exclusive licensing agreement for Idorsia's daridorexant in China. Jinsheng Ren,Chairman and...
Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA
--Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food and Drug Administration (FDA) to conduct a Phase Ib study in patients with monkeypox virus disease --Preclinical studies show that ASC10-A, active metabolite of double prodrug ASC10, has potent antiviral activities against both monkeypox and SARS-CoV-2 viruses HANGZHOU,...
Green Goo Announces NFL Linebacker Shaq Thompson as Brand Ambassador
Plant-based body care brand launches Rub It In campaign and ticket giveaway to football's biggest game in Glendale, AZ on February 12, 2023 LYONS, Colo., Nov. 16, 2022 /PRNewswire/ -- The plant-based Sierra Sage Herbs body care brand, Green Goo, is proud to announce Shaq Thompson, National Football League (NFL) linebacker and...
Tianlong Showcases Innovative Smart PCR Lab Solution at Medica 2022
XI'AN, CHINA, Nov. 15, 2022 /PRNewswire/ -- From November 14 to 17, Tianlong's newly-launched smart PCR lab solution will showcase at Medica 2022 in Dusseldorf, Germany. The innovative smart PCR lab solution from Tianlong can maximize resources by making the best use of people, space, and equipment, and empower the PCR laboratory with high productivity and high efficiency. ...
Reistone Biopharma’s oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic Dermatitis
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- Reistone Biopharma (Reistone), a leading biotech company focused on development of innovative medicines for immune and inflammation diseases, today announced positive results from a Phase III study – QUARTZ3 (NCT04875169) evaluating the efficacy and safety of once daily Ivarmacitinib as monotherapy in adults and adolescents with...
Island to present at World Antiviral Congress 2022
MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that CEO and Managing Director, Dr David Foster will present at the World Antiviral Congress 2022 in San Diego, USA which runs from 28 November – 1 December 2022. The World Antiviral Congress is an invitation...
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue
Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue tops KRW 40.4 billion Fexuclue, a new drug released last July, shows steep growth in market share in Korea Nabota enters the European market and Fexuclue enters wide use as in prescriptions for gastritis indications, leading to expectations...
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in the pharmaceutical division driven by product portfolio expansion and strong sales in major products R&D expenses for the quarter increased by 63%, reflecting the preparation of a Phase 3 study in myasthenia gravis (MG) in...
EDAN Took Its Solutions up a Notch at MEDICA 2022
DUSSELDORF, Germany, Nov. 15, 2022 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ) demonstrated its range of latest innovations at MEDICA, the premiere global medical trade show held at Dusseldorf, Germany, from Nov. 14 to 17, 2022. Five new products are presented to bring a huge surprise to more than 120,000 visitors from over 150 countries, and show EDAN's effort to...
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which...
